Design Therapeutics, Inc. (DSGN)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 80K 160K 240K Q4 '20: 226K Q4 '25: 0 Q1 '26: 0 Q2 '26: 0 Q4 '20 Q4 '25 Q1 '26 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-90M -60M -30M 0 30M 60M 90M Q4 '20: -8.3M Q1 '21: -13.4M Q2 '21: -19.6M Q3 '21: -28.6M Q4 '21: -35.8M Q1 '22: -43.5M Q2 '22: -51.5M Q3 '22: -59.3M Q4 '22: -67.6M Q1 '23: -75.9M Q2 '23: -82.8M Q3 '23: -82.5M Q4 '23: -78.2M Q1 '24: -70.9M Q2 '24: -63.4M Q3 '24: -60.8M Q4 '24: -62.4M Q1 '25: -68.4M Q2 '25: -74.9M Q3 '25: -78M Q4 '25: -79.5M Q1 '26: -78.8M Q2 '26: -79.4M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-90M -60M -30M 0 30M 60M 90M Q4 '20: -8.3M Q1 '21: -13.1M Q2 '21: -19.3M Q3 '21: -28.3M Q4 '21: -35.5M Q1 '22: -43.3M Q2 '22: -50.6M Q3 '22: -57M Q4 '22: -63.3M Q1 '23: -69.3M Q2 '23: -74.3M Q3 '23: -72.4M Q4 '23: -66.9M Q1 '24: -58.7M Q2 '24: -50.5M Q3 '24: -47.8M Q4 '24: -49.6M Q1 '25: -56.2M Q2 '25: -63.5M Q3 '25: -67.4M Q4 '25: -69.8M Q1 '26: -69.7M Q2 '26: -70.8M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-75M -50M -25M 0 25M 50M 75M Q4 '20: -8.7M Q1 '21: -9.7M Q2 '21: -16.7M Q3 '21: -23M Q4 '21: -29.4M Q1 '22: -37.5M Q2 '22: -39.7M Q3 '22: -45.5M Q4 '22: -51.3M Q1 '23: -56.9M Q2 '23: -60.2M Q3 '23: -60.9M Q4 '23: -58.6M Q1 '24: -53.6M Q2 '24: -51M Q3 '24: -46M Q4 '24: -43.1M Q1 '25: -47.5M Q2 '25: -50.6M Q3 '25: -52.3M Q4 '25: -54.4M Q1 '26: -54M Q2 '26: -55.1M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-75M -50M -25M 0 25M 50M 75M Q3 '21: -24.2M Q4 '21: -30.9M Q1 '22: -39.1M Q2 '22: -41.4M Q3 '22: -46.4M Q4 '22: -52.2M Q1 '23: -57.8M Q2 '23: -61M Q3 '23: -61.4M Q4 '23: -58.8M Q1 '24: -53.9M Q2 '24: -51.5M Q3 '24: -46.4M Q4 '24: -43.4M Q1 '25: -47.7M Q2 '25: -50.8M Q3 '25: -52.4M Q4 '25: -54.6M Q1 '26: -54.1M Q2 '26: -55.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 25M 50M 75M Q2 '21: 55.1M Q3 '21: 55.2M Q1 '22: 55.5M Q2 '22: 55.7M Q3 '22: 55.8M Q1 '23: 55.9M Q2 '23: 55.9M Q3 '23: 56M Q1 '24: 56.5M Q2 '24: 56.6M Q3 '24: 56.6M Q1 '25: 56.8M Q2 '25: 56.9M Q3 '25: 57M Q1 '26: 61.4M Q2 '26: 62.5M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.50 -1.00 -0.50 0.00 0.50 1.00 1.50 Q4 '20: -0.54 Q1 '21: -0.81 Q2 '21: -0.89 Q3 '21: -1.01 Q4 '21: -0.86 Q1 '22: -0.79 Q2 '22: -0.92 Q3 '22: -1.03 Q4 '22: -1.14 Q1 '23: -1.25 Q2 '23: -1.34 Q3 '23: -1.30 Q4 '23: -1.20 Q1 '24: -1.05 Q2 '24: -0.90 Q3 '24: -0.85 Q4 '24: -0.88 Q1 '25: -0.99 Q2 '25: -1.12 Q3 '25: -1.19 Q4 '25: -1.22 Q1 '26: -1.20 Q2 '26: -1.18 Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.